Tesla's Nevada Gigafactory to Begin Semi Truck Production by End 2025

Published 6 hours agoTSLA

Tesla's Nevada Gigafactory to Begin Semi Truck Production by End 2025

Tesla announced that it will start producing its electric Semi trucks at its Gigafactory in Nevada by the end of 2025. The company has set the timeline to begin production with an aim to scale up operations throughout 2026. As reported by Reuters, this development promises to boost the company’s manufacturing capacity for its much-awaited electric Semi trucks.

The Nevada Gigafactory is poised to have an annual production capacity of 50,000 units. Tesla's journey with the Semi has seen previous delays; the electric vehicle maker initially targeted 2019 for production, with plans to reach 50,000 units by 2024. These plans were postponed primarily due to tariffs as high as 145% on Chinese goods imposed during the Trump administration, which disrupted components' supplies for the Semi and Cybercab models from China.

Despite the delays, the recent announcement has positively impacted Tesla’s stock value, with shares appreciating by 21.9%, according to the Financial Times. The electric vehicle manufacturer seems to be aligning its strategies to overcome past challenges and enhance its position in the commercial electric vehicle market.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Farmers & Merchants Bancorp Sees Strong Q4 and Full-Year Earnings Growth

Farmers & Merchants Bancorp Sees Strong Q4 and Full-Year Earnings Growth

19 minutes agoFMAO

Farmers & Merchants Bancorp, Inc. (Nasdaq: FMAO) released its financial results for the fourth quarter and the entire year of 2024 on February 12, 2025. The company reported a significant rise in net income during the fourth quarter, with earnings reaching $8.4 million, or $0.61 per share. This marks a 51.2% increase compared to $5.5 million, or $0.41 per share, in the same period of 2023. For the full year of 2024, net income rose to $17.6 million, up from $17.2 million the previous year. Supporting these results, the asset quality of the company improved notably. Nonperforming loans were reduced to $3.1 million by the end of 2024, a substantial decrease from $22.4 million a year earlier. The allowance for credit losses was robust, covering 826.70% of nonperforming loans. Operational efficiency also showed positive trends, with the efficiency ratio improving to 59.82% in Q4 2024 from 69.23% in Q4 2023. In terms of capital and liquidity, Farmers & Merchants Bancorp maintained a strong position with a Tier 1 leverage ratio of 8.12%. The bank closed 2024 with over $690 million in contingent funding sources and improved its cash-to-assets ratio to 5.3% from 4.3% at the end of 2023. Reuters noted that the board approved a 3.8% increase in the annual dividend, marking the 30th consecutive year of dividend growth since 1994. These developments reflect the company's strategic focus on enhancing financial performance and delivering value to shareholders.

Novartis Boosts 2025 Earnings Outlook Amid Strong Q1 Results

Novartis Boosts 2025 Earnings Outlook Amid Strong Q1 Results

34 minutes agoNVS

Novartis has raised its earnings expectations for 2025, following an impressive first-quarter performance fueled by significant sales growth of its key drugs. The pharmaceutical giant now anticipates a 'low double-digit' percentage increase in operating income for 2025, an upgrade from the earlier forecast of 'high single to low double-digit' growth, as reported by Reuters. In the first quarter, Novartis saw substantial sales growth from key products, driving the company's strong performance. Kisqali's sales jumped by 43% year-over-year, Kesimpta's by 28%, and Leqvio's by a remarkable 119%. Additionally, Novartis recorded a 22% increase in operating income for 2024. The company also proposed a dividend increase to CHF 3.50 per share for 2024, marking a 6.1% rise. Despite looming patent expirations, including that of Entresto, Novartis CEO Vas Narasimhan remains confident, expressing belief in maintaining average annual sales growth of at least 5% through 2028. This optimism stems from a robust pipeline of new drug offerings and innovation, ensuring the company remains a formidable player in the pharmaceutical market.

Deutsche Bank Exceeds Expectations with 39% Profit Surge

Deutsche Bank Exceeds Expectations with 39% Profit Surge

49 minutes agoDB

Deutsche Bank has reported a remarkable 39% jump in its first-quarter profit for 2025, significantly surpassing analyst expectations. The bank's net profit climbed to €1.78 billion ($2.03 billion), a notable increase from €1.28 billion during the same period last year, according to Reuters. This surge is largely attributed to robust performance in its investment banking division, particularly through strong revenue growth in bond and currency trading amid volatile market conditions. The bank views this as a step towards achieving its 2025 targets, as part of a three-year strategic plan that is effectively coming to fruition. Christian Sewing, the CEO of Deutsche Bank, expressed confidence in a recent statement, stating, "We are on track for delivery on all our 2025 targets." His remarks underscore the bank's commitment to its strategic objectives, reinforcing its strong operational performance in a stabilizing economic landscape.

HSBC Unveils $3 Billion Buyback Amid Q1 Profit Slip

HSBC Unveils $3 Billion Buyback Amid Q1 Profit Slip

1 hours agoHSBC

HSBC has announced a $3 billion share buyback even as it reported a 25% drop in first-quarter profits. The bank saw its pre-tax profit fall to $9.5 billion, down from $12.7 billion in the same period last year. One of the contributing factors to this decline was $900 million in anticipated credit losses, partly fueled by $150 million related to global tariff tensions, as noted by Reuters. Despite the profit setback, HSBC remains focused on returning value to shareholders with the $3 billion buyback, which forms part of a total of $7 billion in buybacks announced this year. The bank plans to complete the latest buyback by February 2026. Additionally, HSBC has declared an interim dividend of $0.10 per share, reflecting a strategic commitment to shareholder returns. HSBC continues to pursue efficiency and growth plans, aiming to cap expense increases at 3% in 2025 and cut annual costs by $1.5 billion by the end of 2026. Investments are being redirected from non-core sectors to focus on growth opportunities in wholesale transaction banking and Asian wealth management. The bank is also conducting a strategic review of its operations in Malta, in line with its effort to optimize smaller businesses globally.